Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 10 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.
Official title: A Single-Dose and Multiple-Ascending Dose Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
216
Start Date
2025-04-23
Completion Date
2026-04
Last Updated
2026-03-27
Healthy Volunteers
Yes
Conditions
Interventions
LY4086940
Administered orally
Placebo
Administered orally
LY4086940
Administered IV
Locations (5)
Fortrea Clinical Research Unit
Daytona Beach, Florida, United States
Clinical Pharmacology of Miami
Miami, Florida, United States
Fortrea Clinical Research Unit
Dallas, Texas, United States
Endeavor Clinical Trials
San Antonio, Texas, United States
Lilly Centre for Clinical Pharmacology
Singapore, Singapore